LEO Pharma's Xamiol approved in Europe
This article was originally published in Scrip
LEO Pharma's topical scalp psoriasis treatment Xamiol, a gel formulation of betametasone dipropionate and calcipotriol, has been approved in 16 European countries, including France, Germany and the UK.
You may also be interested in...
Amgen's investigational bone loss treatment denosumab more than halves osteoporosis patients' risk of new vertebral fractures, new data from a pivotal Phase III trial show.
Gilead Scienceswill need to conduct another clinical trial of its investigational cystic fibrosis treatment aztreonam lysine for inhalation before the drug can be approved, the US FDAhas said.